Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses

Article activity feed

1. Version published to 10.1021/acsinfecdis.0c00761

   Mar 1, 2021
2. 

   ScreenIT

   Nov 2, 2020

   SciScore for 10.1101/2020.10.30.362335: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Experimental Models: Cell Lines
   Sentences	Resources
   Human rhabdomyosarcoma (RD), Vero E6, Huh-7, HEK293T expressing ACE2 (ACE2/293T), and HCT-8 cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM); Caco-2 and MRC-5 cell lines were maintained in Eagle’s Minimum Essential Medium (EMEM).	HEK293T suggested: None HCT-8 suggested: ICLC Cat# HTL99005, RRID:CVCL_2478) Caco-2 suggested: None
   HCoV-OC43 was propagated in RD cells; HCoV-NL63 was propagated in MRC-5 cells.	MRC-5 suggested:…

   SciScore for 10.1101/2020.10.30.362335: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Experimental Models: Cell Lines
   Sentences	Resources
   Human rhabdomyosarcoma (RD), Vero E6, Huh-7, HEK293T expressing ACE2 (ACE2/293T), and HCT-8 cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM); Caco-2 and MRC-5 cell lines were maintained in Eagle’s Minimum Essential Medium (EMEM).	HEK293T suggested: None HCT-8 suggested: ICLC Cat# HTL99005, RRID:CVCL_2478) Caco-2 suggested: None
   HCoV-OC43 was propagated in RD cells; HCoV-NL63 was propagated in MRC-5 cells.	MRC-5 suggested: ICLC Cat# HL95001, RRID:CVCL_0440)
   HCoV-229E was obtained from Dr. Bart Tarbet (Utah State University) and amplified in Huh-7 or MRC-5 cells; The Urbani strain of severe acute respiratory syndrome coronavirus (SARS-CoV) and the EMC/2012 strain Middle East respiratory syndrome coronavirus (MERS-CoV) were obtained from the Centers for Disease Control and Prevention.	Huh-7 suggested: None
   Vero 76 cells were obtained from the American Type Culture Collection.	Vero 76 suggested: IZSLER Cat# BS CL 101, RRID:CVCL_0603)
   Pseudovirus neutralization assay: A pseudotype HIV-1-derived lentiviral particles bearing SARS-CoV-2 spike and a lentiviral backbone plasmid encoding luciferase as reporter was produced in HEK293 T cells engineered to express the SARS-CoV-2 receptor, ACE2 (ACE2/293 T cells), as previously described.	HEK293 suggested: None
   21 The pseudovirus was then used to infect Vero E6 cells in 96-well plates in the presence of DMSO or serial concentrations of E-64d, boceprevir, calpain inhibitors II and XII, and GC-376.	Vero E6 suggested: None
   42 Briefly, RD cells were seeded at 1 ×105 cells/well in 12-well plate.	RD suggested: None
   HCoV-OC43, HCoV-229E, and HCoV-NL63 CPE assays: Antiviral activities of boceprevir, calpain inhibitors II and XII, and GC-376 against HCoV-229E, HCoV-NL63 and HCoV-OC43 were tested in CPE assays as previously described44 with minor modifications.	HCoV-NL63 suggested: RRID:CVCL_RW88)
   Software and Algorithms
   Sentences	Resources
   The initial velocity was plotted against the FRET concentration with the classic Michaelis–Menten equation in Prism 8 software.	Prism suggested: (PRISM, RRID:SCR_005375)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2020.10.30.362335v1 on bioRxiv

   Nov 1, 2020